Evofem Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
Independent Registered Public Accounting Firm’s Fees
The following table shows the fees billed by BPM for the audit of our annual consolidated financial statements for the last two fiscal years.
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Audit Fees (1) | $688,980 | $565,681 |
| Audit Related Fees | - | - |
| Tax Fees (2) | - | - |
| All Other Fees | - | - |
| Total | $688,980 | $565,681 |
| (1) | Audit Fees represent fees and out-of-pocket expenses, whether or not yet invoiced, for professional services provided in connection with the audit of the Company’s consolidated financial statements, the review of the Company’s quarterly consolidated financial statements, and audit services provided in connection with other regulatory filings. |
| (2) | Tax fees represent fees and out-of-pocket expenses for professional services for tax compliance, tax advice or tax return preparations. |
Pre-Approval Policies and Procedures
The Audit Committee annually reviews and pre-approves certain audit and non-audit services that may be provided by our independent registered public accounting firm and establishes and pre-approves the aggregate fee level for these services. Any proposed services that would cause us to exceed the pre-approved aggregate fee amount must be pre-approved by the Audit Committee. All audit services for 2023 and 2024 were pre-approved by the Audit Committee.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.